Q1 2022 revenue: +9.03% to €49.36m
Effective change of name: the Pharmagest Group becomes the Equasens Group
• The Extraordinary General Meeting of May 6, 2022 adopted the resolution to change the name of the Pharmagest Group to become the Equasens Group.
• The Group’s Q1 2022 revenue increased by +9.03% to €49.36 million (+7% to €48.44 million on a like-for-like basis).
• The Group confirms its development momentum and its growth ambitions in 2022.
Outlook 2022
The Group intends to maintain its growth momentum, in line with previous quarters, and confirms its ambitions for the coming months.
The referencing of its software solutions and the implementation of funding (Wave 1) of the Ségur du Numérique en Santé government program will consolidate this progress over the coming quarters and enable the Group to consolidate its position as a key player in the world. of Health.
The entire press release is online on the Group’s new website: www.equasens.com
Investors section/Press releases
EQUASENS is listed on Euronext Paris™ – Compartment A
Indices: MSCI GLOBAL SMALL CAP – GAÏA Index 2020 – CAC® SMALL and CAC® All-Tradable by inclusion
Included in the European Rising Tech label
Eligible for the Deferred Settlement Service (SRD) and the PEA-PME scheme
ISIN: FR0012882389 – Mnemonic code to be confirmed